AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25682524 — intervention group
Group type: COMPARATOR
Intervention: Brief Psychotherapy (average of six sessions)
Number of subjects: 28
Study 25682524 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Psychotherapy (average of five sessions)
Number of subjects: 28
Study 25682524 — intervention group
Group type: EXPERIMENTAL
Intervention: RIME intervention
Number of subjects: 28
Study 25682524 — intervention group
Group type: EXPERIMENTAL
Intervention: RIME Group
Number of subjects: 28
Study 25682524 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 28
Study 24406208 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Index
Number of subjects: 0
Study 24406208 — intervention group
Group type: COMPARATOR
Intervention: Standard DC
Number of subjects: 0
Study 22231013 — intervention group
Group type: COMPARATOR
Intervention: Intravenous human albumin (HA) 20 gr infused over 1 hour
Number of subjects: 138
Study 22231013 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cabergoline (Cb2) 0.5 mg per day for 7 days starting on oocyte pickup day
Number of subjects: 138
Study 19755670 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium salicylate (4.5 g/day)
Number of subjects: 6
Study 19755670 — intervention group
Group type: COMPARATOR
Intervention: Intralipid plus heparin (IH)
Number of subjects: 6
Study 19755670 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (SAL)
Number of subjects: 6
Study 19755670 — intervention group
Group type: COMPARATOR
Intervention: Oral sodium salicylate (SS)
Number of subjects: 6
Study 17456651 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg ketorolac
Number of subjects: 37
Study 17456651 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg ketorolac
Number of subjects: 37
Study 17456651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 17456651 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative morphine administration
Number of subjects: 37
Study 14969370 — intervention group
Group type: EXPERIMENTAL
Intervention: Slot Class III composite restorations
Number of subjects: 36
Study 14969370 — intervention group
Group type: COMPARATOR
Intervention: Dovetail Class III composite restorations
Number of subjects: 36
Study 12140475 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate spray (FP), 50 microg two dose unit sprays, 4 times daily for 6 weeks
Number of subjects: 48
Study 12140475 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone sodium phosphate mouthrinse (BSP), 500 microg, 4 times daily for 6 weeks
Number of subjects: 48
Study 10346511 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Voice Recognition (IVR)
Number of subjects: 229
Study 10346511 — intervention group
Group type: COMPARATOR
Intervention: Live telephone interview
Number of subjects: 229
Study 7876615 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine (0, 1, and 12 months schedule for adults; 0, 1, and 6; 0, 1, and 2; or 0, 1, and 12 months for children)
Number of subjects: 307
Study 2230438 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical analysis methods for handling equivocal subjects
Number of subjects: 0
Study 341952 — intervention group
Group type: EXPERIMENTAL
Intervention: House dust mite hyposensitization
Number of subjects: 14
Study 341952 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 14
Study 30901440 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplement for 90 days (treatment group)
Number of subjects: 152
Study 30901440 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control (control group)
Number of subjects: 152
Study 30901440 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose Vitamin D3 supplement (treatment group)
Number of subjects: 152
Study 30901440 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose Vitamin D3 supplement (treatment group)
Number of subjects: 152
Study 30901440 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplement (treatment group)
Number of subjects: 152
Study 28608438 — intervention group
Group type: EXPERIMENTAL
Intervention: NUTRITION (oral nutritional supplementation enriched with leucine, vitamin D, and omega-3 fatty acids)
Number of subjects: 81
Study 28608438 — intervention group
Group type: COMPARATOR
Intervention: PLACEBO
Number of subjects: 81
Study 28608438 — intervention group
Group type: COMPARATOR
Intervention: Both groups (NUTRITION and PLACEBO)
Number of subjects: 81
Study 26534930 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine replacement therapy (DRT)
Number of subjects: 320
Study 26534930 — intervention group
Group type: COMPARATOR
Intervention: No dopamine replacement therapy (not on DRT)
Number of subjects: 320
Study 25175478 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression care for people with cancer
Number of subjects: 500
Study 25175478 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 500
Study 23026180 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) nasal aerosol at 320 μg/day
Number of subjects: 340
Study 23026180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 340
Study 18923109 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk behaviors including frequent public drunkenness, early age of illicit drug use, involvement in the drug economy, tattooing, injecting drugs, unprotected sex
Number of subjects: 1189
Study 18923109 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV, HCV, and herpes simplex virus type 2 (HSV-2) infection
Number of subjects: 1189
Study 17967219 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.5% (10 mg)
Number of subjects: 60
Study 17967219 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.5% (10 mg)
Number of subjects: 60
Study 17967219 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 5 microg
Number of subjects: 60
Study 17967219 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 10 or 20 microg
Number of subjects: 60
Study 15337693 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation coronary stents
Number of subjects: 1228
Study 11859651 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine 2.5 mg
Number of subjects: 470
Study 11859651 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine 5 mg
Number of subjects: 470
Study 11859651 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine 10 mg
Number of subjects: 470
Study 11859651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 470
Study 10024188 — intervention group
Group type: EXPERIMENTAL
Intervention: Tarnobrzeg population (rural)
Number of subjects: 2443
Study 10024188 — intervention group
Group type: COMPARATOR
Intervention: Warsaw population (urban)
Number of subjects: 2443
Study 10024188 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 2443
Study 10024188 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in HDL‐cholesterol (15 mg/dl)
Number of subjects: 2443
Study 8179048 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help package
Number of subjects: 683
Study 8179048 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition course
Number of subjects: 683
Study 8179048 — intervention group
Group type: COMPARATOR
Intervention: Screening only (control group)
Number of subjects: 683
Study 3429102 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-methoxy psoralen (5-MOP) PUVA
Number of subjects: 0
Study 3429102 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-MOP Re-PUVA with daily oral etretinate
Number of subjects: 0
Study 3429102 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-MOP Re-PUVA
Number of subjects: 0
Study 3429102 — intervention group
Group type: EXPERIMENTAL
Intervention: Doses adapted to total body surface
Number of subjects: 0
Study 3429102 — intervention group
Group type: EXPERIMENTAL
Intervention: Emollient creams, tar gels, nonsteroidal scalp applications
Number of subjects: 0
Study 31932084 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg every 2 weeks
Number of subjects: 23
Study 29549751 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitor the CS+ (N=19)
Number of subjects: 57
Study 29549751 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoid the CS+ and attend to another stimulus (N=18)
Number of subjects: 57
Study 29549751 — intervention group
Group type: COMPARATOR
Intervention: No attention manipulation control (N=20)
Number of subjects: 57
Study 27632197 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol intake (10 g ethanol per day)
Number of subjects: 156386
Study 27632197 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusion of heavy drinkers and the elderly
Number of subjects: 156386
Study 27632197 — intervention group
Group type: COMPARATOR
Intervention: ALDH2 variant rs671
Number of subjects: 156386
Study 24905901 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen-based measurement paradigms
Number of subjects: 42
Study 24905901 — intervention group
Group type: COMPARATOR
Intervention: Naturalistic measurement paradigms
Number of subjects: 42
Study 22840829 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week exercise intervention program consisting of supervised weekly 60-minute sessions and unsupervised 30 minutes of aerobic exercises 4 times each week.
Number of subjects: 40
Study 22840829 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week exercise intervention program
Number of subjects: 40
Study 22840829 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week exercise intervention program (exercising more than 90 minutes per week)
Number of subjects: 40
Study 20194702 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg posaconazole oral suspension twice daily for 8 days with a high-fat meal
Number of subjects: 30
Study 18603414 — intervention group
Group type: EXPERIMENTAL
Intervention: Structural magnetic resonance imaging
Number of subjects: 50
Study 16084803 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 39
Study 16084803 — intervention group
Group type: COMPARATOR
Intervention: Aerobic Endurance Training (ET)
Number of subjects: 39
Study 12451009 — intervention group
Group type: COMPARATOR
Intervention: Postexercise cardiovascular dynamics in RVOTR patients
Number of subjects: 79
Study 12451009 — intervention group
Group type: COMPARATOR
Intervention: Postexercise cardiovascular dynamics in control subjects
Number of subjects: 79
Study 12451009 — intervention group
Group type: COMPARATOR
Intervention: Postexercise cardiovascular dynamics in patients after closure of an atrioventricular septal defect
Number of subjects: 79
Study 10511057 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 microCi [14C‐N‐methyl]‐erythromycin intravenously
Number of subjects: 20
Study 10511057 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg midazolam intravenously
Number of subjects: 20
Study 10511057 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg midazolam orally
Number of subjects: 20
Study 8552930 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants in Reykjavik
Number of subjects: 2202
Study 8552930 — intervention group
Group type: COMPARATOR
Intervention: Participants in Sweden
Number of subjects: 2202
Study 8552930 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with gastroesophageal reflux (GER)
Number of subjects: 2202
Study 8552930 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 2202
Study 8384659 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, etoposide, vincristine, methotrexate (CEV-M)
Number of subjects: 113
Study 8384659 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, doxorubicin, vincristine (CAV)
Number of subjects: 113
Study 2429908 — intervention group
Group type: EXPERIMENTAL
Intervention: inosine pranobex (Imunovir)
Number of subjects: 165
Study 2429908 — intervention group
Group type: COMPARATOR
Intervention: conventional treatment
Number of subjects: 165
Study 2429908 — intervention group
Group type: EXPERIMENTAL
Intervention: inosine pranobex (Imunovir) with conventional treatment
Number of subjects: 165
Study 2429908 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunological studies
Number of subjects: 165
Study 28717826 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-Catheter Approach (SCA)
Number of subjects: 256
Study 28717826 — intervention group
Group type: COMPARATOR
Intervention: Two-Catheter Approach (TCA)
Number of subjects: 256
Study 25844870 — intervention group
Group type: EXPERIMENTAL
Intervention: Super LED bed (group 2)
Number of subjects: 200
Study 25844870 — intervention group
Group type: COMPARATOR
Intervention: Triple fluorescent tube units (group 1)
Number of subjects: 200
Study 26081179 — intervention group
Group type: EXPERIMENTAL
Intervention: Single maximal inhalation with breath-hold (200 μg salbutamol)
Number of subjects: 82
Study 26081179 — intervention group
Group type: COMPARATOR
Intervention: 5 tidal breaths (200 μg salbutamol)
Number of subjects: 82
Study 23292207 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise treatment
Number of subjects: 53
Study 23292207 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 53
Study 21475140 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction lipectomy
Number of subjects: 32
Study 21475140 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 32
Study 18971135 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine-soaked Spongostan plus local lignocaine infiltration 1% up to 20 mL
Number of subjects: 99
Study 18971135 — intervention group
Group type: COMPARATOR
Intervention: Local lignocaine infiltration 1% up to 20 mL
Number of subjects: 99
Study 17198555 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary metastasectomy
Number of subjects: 0
Study 17198555 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete resection of lung metastases
Number of subjects: 0
Study 17198555 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical procedures
Number of subjects: 0
Study 12657237 — intervention group
Group type: EXPERIMENTAL
Intervention: Hetastarch (6% hydroxyethyl starch)
Number of subjects: 20
Study 12657237 — intervention group
Group type: COMPARATOR
Intervention: Peritoneal dialysis solution (1.5% dextrose)
Number of subjects: 20
Study 11119198 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal diclofenac 2 mg.kg(‐1) following oral placebo premedication
Number of subjects: 125
Study 11119198 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. flurbiprofen 1 mg.kg(‐1) following placebo premedication
Number of subjects: 125
Study 11119198 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clonidine premedication
Number of subjects: 125
Study 11119198 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal diclofenac 2 mg.kg(‐1) following clonidine
Number of subjects: 125
Study 11119198 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. flurbiprofen 1 mg.kg(‐1) following clonidine
Number of subjects: 125
Study 7546970 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketac Fil
Number of subjects: 37
Study 7546970 — intervention group
Group type: COMPARATOR
Intervention: Ketac Silver
Number of subjects: 37
Study 2252363 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin (400 mouse units)
Number of subjects: 9
Study 2252363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 7240113 — intervention group
Group type: EXPERIMENTAL
Intervention: imipramine
Number of subjects: 79
Study 7240113 — intervention group
Group type: EXPERIMENTAL
Intervention: doxepin
Number of subjects: 79
Study 31771756 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple barriers to adherence (e.g., forgetfulness, health beliefs)
Number of subjects: 1069
Study 31771756 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-white patients
Number of subjects: 1069
Study 31771756 — intervention group
Group type: EXPERIMENTAL
Intervention: Single/unpartnered status
Number of subjects: 1069
Study 31771756 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco use
Number of subjects: 1069
Study 31771756 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor glycemic control
Number of subjects: 1069
Study 30666367 — intervention group
Group type: EXPERIMENTAL
Intervention: HFNC
Number of subjects: 192
Study 30666367 — intervention group
Group type: COMPARATOR
Intervention: SMO
Number of subjects: 192
Study 27416891 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 50
Study 27416891 — intervention group
Group type: COMPARATOR
Intervention: Etanercept
Number of subjects: 50
Study 26062024 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 6
Study 26062024 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 6
Study 26062024 — intervention group
Group type: COMPARATOR
Intervention: Standard blind trials
Number of subjects: 6
Study 26062024 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-by-two blind trials
Number of subjects: 6
Study 23118346 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorb BVS in small vessels (RVD <2.5 mm)
Number of subjects: 101
Study 23118346 — intervention group
Group type: COMPARATOR
Intervention: Absorb BVS in large vessels (RVD ≥2.5 mm)
Number of subjects: 101
Study 21646910 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose 30-60 ml twice per day (GpB)
Number of subjects: 160
Study 21646910 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics 110 billion CFU twice per day (GpC)
Number of subjects: 160
Study 21646910 — intervention group
Group type: EXPERIMENTAL
Intervention: L-ornithine L-aspartate (LOLA) 6 g three times per day (GpD)
Number of subjects: 160
Study 21646910 — intervention group
Group type: COMPARATOR
Intervention: No treatment (GpA)
Number of subjects: 160
Study 19372524 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent housing with intensive case management
Number of subjects: 105
Study 19372524 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 105
Study 16761194 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe (10 mg/day for 90 days)
Number of subjects: 12
Study 16761194 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 15324976 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk information presented in vertical bars
Number of subjects: 44
Study 15324976 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk information presented as icons
Number of subjects: 44
Study 15324976 — intervention group
Group type: COMPARATOR
Intervention: Risk information presented in numbers
Number of subjects: 44
Study 11430965 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 200 mg and vaginal misoprostol 800 microg (used 48 hours after mifepristone)
Number of subjects: 4393
Study 11430965 — intervention group
Group type: COMPARATOR
Intervention: Vaginal misoprostol inserted at 1, 2, or 3 days after mifepristone administration
Number of subjects: 4393
Study 9468354 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroleptic drugs
Number of subjects: 0
Study 9468354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9468354 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic treatment with neuroleptics
Number of subjects: 0
Study 9468354 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncompliance with medication
Number of subjects: 0
Study 9468354 — intervention group
Group type: EXPERIMENTAL
Intervention: Current drug abuse
Number of subjects: 0
Study 9468354 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol and substance abuse
Number of subjects: 0
Study 8534381 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice containing 5.0% potassium nitrate, 1.3% soluble pyrophosphate, 1.5% PVM/MA copolymer and 0.243% sodium fluoride in a silica base
Number of subjects: 115
Study 8534381 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice (0.243% sodium fluoride silica-based)
Number of subjects: 115
Study 8534381 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice containing potassium nitrate, soluble pyrophosphate and PVM/MA copolymer
Number of subjects: 115
Study 8534381 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 115
Study 3226418 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous hyperthermic peritoneal perfusion (CHPP) with an anticancer drug
Number of subjects: 0
Study 3226418 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 0
Study 30889160 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic carpal tunnel release (ECTR)
Number of subjects: 60
Study 30889160 — intervention group
Group type: COMPARATOR
Intervention: Open carpal tunnel release (OCTR)
Number of subjects: 60
Study 30889160 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ECTR and OCTR
Number of subjects: 60
Study 30889160 — intervention group
Group type: EXPERIMENTAL
Intervention: Quick Disabilities of the Arm, Shoulder and Hand (QuickDASH)
Number of subjects: 60
Study 28504521 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher family dinner frequency
Number of subjects: 160
Study 28504521 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower parent dinnertime media use
Number of subjects: 160
Study 28504521 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dinnertime routines
Number of subjects: 160
Study 28504521 — intervention group
Group type: COMPARATOR
Intervention: Parent BMI scores
Number of subjects: 160
Study 25185603 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine ER 120 mg
Number of subjects: 56
Study 25185603 — intervention group
Group type: COMPARATOR
Intervention: Imipramine 25 mg
Number of subjects: 56
Study 25185603 — intervention group
Group type: COMPARATOR
Intervention: Cyclobenzaprine 10 mg
Number of subjects: 56
Study 25185603 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin 0.4 mg
Number of subjects: 56
Study 25185603 — intervention group
Group type: COMPARATOR
Intervention: Solifenacin 5 mg
Number of subjects: 56
Study 25185603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 22037770 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis use
Number of subjects: 267
Study 22037770 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis dose
Number of subjects: 267
Study 22037770 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in cannabis dose
Number of subjects: 267
Study 22037770 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater cannabis exposure
Number of subjects: 267